Healthcare
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end viral vector manufacturing capabilitiesPartnership further demonstrates momentum across OXB’s AAV business and ongoing client base diversification Oxford, UK – 16 July 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has signed an agreement wi
About this update from Oxford Biomedica Plc
Oxford, UK – 16 July 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has signed an agreement with Plowshare Therapies ("Plowshare"), a biotechnology company developing gene therapies for rare genetic diseases. Under the agreement, OXB will provide process development and AAV GMP manufacturing services to Plowshare, with the potential to support additional programmes and later-stage manufacturing as Plowshare's pipeline advances. Plowshare's programme will be supported from OXB's FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, underscoring the site's growing role as a key hub for AAV manufacturing within OXB's global network. The collaboration highlights continued demand for OXB's portfolio of capabilities in the viral vector space and reflects the strategic importance of its expanded US footprint, with the site attracting a significant number of new clients since its acquisition in October 2025. The partnership is rooted in a shared commitment between OXB and Plowshare to advance transformative therapies for patients living with debilitating conditions, leveraging more than three decades of OXB's viral vector development and manufacturing expertise. Dr. Sébastien Ribault, Chief Business Officer of OXB, said: "This latest partnership demonstrates the strategic value of our expanded US manufacturing network and reflects the increasing momentum we are seeing across our AAV business since the acquisition. By combining our deep expertise in viral vector development and GMP manufacturing with Plowshare's innovative rare disease programme, we look forward to supporting the advancement of potentially transformative therapies for patients with significant unmet medical needs." Kevin A. Strauss, MD, Founder and Chief Medical Officer of Plowshare Therapies, said: "Plowshare was created alongside the community it serves to get the best therapeutic science to patients who need it most. For any child with a rare disease, we demand manufacturing of the highest rigour. In OXB, we found a partner whose standards match our own." -Ends- Enquiries:
View stock analysis, news, and events for Oxford Biomedica Plc